Nanobio platform design and manufacturing technology

FET Biosensor Technology

Rapid diagnosis platform for various diseases through biomarkers such as pancreatic cancer diagnosis device, and diabetes bloodless blood device.

Sensor Chip Design

– FET device characteristic design (P-Type CNT and n-type oxide)
– Adjustment of width, length, etc. between electrodes
– Characteristic design suitable for biomarker measurement

Oxide and SWCNT application technology

– Form fine network patterns with nano-inkjet or sputter
– Optimization of ink dispersion during process and securing sputter condition control technology
– Control of FET surface adhesion by polymerizing the surface

Nanobio platform design and manufacturing technology

Bio antibody technology

Rapid diagnosis platform for various diseases through biomarkers such as pancreatic cancer diagnosis device, and diabetes bloodless blood device.

Bioantibody surface treatment and design technology (prior art)

Average glycation value (using 2 channels)

Each density value was measured from the glycosylated albumin (gHSA) and total albumin (HSA) standard curves, and the percentage value of gHSA to total albumin was derived.

Bioantibody surface treatment and performance design (antibody-antigen reaction optimization)

– Channel Design for Ab-Ag Interaction

– FET design and Debye potential control

– Acquired new technology certification_Ministry of Trade, Industry, and Energy in South Korea

Rapid diagnosis platform for various diseases through biomarkers

– One Platform. Endless Possibilities
– Provide laboratory diagnostic results in minutes in home/office
– Detection of biological analytes ranging form Nucleic acids to cellular targets

BIOSENSOR R&D

  1. Pancreatic cancer early biomarker diagnosis

Commercialization of an early stage biomarker diagnostic device for pancreatic cancer

– US company F and ADR company (Results within 1 minute after blood collection (finger))
– Discovery of early biomarkers for pancreatic cancer and obtaining licenses for use
– Oxide field transistor-based diagnostic kit patent application (Ox-TFT)
– ELISA and IHC FDA application & Biomarker patent by ADR company
– US FDA marketing approval (2023) scheduled
– Equipment and chip supply contract to US company F

2. Glycated albumin measuring device for Diabetes

Commercialization of glycosylated albumin measuring device

– Completion of commercialization with ICT R&D voucher support project

– Completed development of Bio-ICT-based portable bloodless diabetes measurement device

– Clinical contract with U. of Maryland Hospital

– Glycated albumin meter with Company T (clinical and FDA in progress) Results within 1 minute of taking a saliva sample

3. Breast cancer T-ELISA commercialization MOU

– Technology development project linked to customers

– Development of 96ch T-ELISA for protein measurement/analysis using printed CNT-FET

– Signed an agreement for joint development of breast cancer marker measurement with EnS Healthcare

4. Real-time CNT-FET myocardial infarction diagnostic kit development

– Technology innovation development project

– Real-time CNT-FET myocardial infarction diagnostic kit development

– Joint commercialization with a company T and exchange of letter of intent to sell in the United States